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Background: Calcitonin gene-related peptide (CGRP) is a 37-amino acid peptide and produced by alternative splicing of the transcript of the calcitonin/CGRP gene. Originally identified as a strong vasodilatory and hypotensive peptide, CGRP is now known to be a pleiotropic molecule distributed in various organs, including the brain.
Method:
In this study, we used CGRP knockout mice (CGRPÀ/À) to examine the actions of endogenous CGRP during cerebral ischemia. To induce acute and chronic cerebral ischemia, mice were subjected to middle cerebral artery occlusion (MCAO) and bilateral common carotid artery stenosis (BCAS).
Results:
In the cerebral cortex of wild-type mice, CGRP expression was upregulated after acute infarction. In CGRPÀ/À subjected to MCAO or BCAS, recovery of cerebral blood flow was slower and exhibited more extensive neuronal cell death. Expression of the inflammatory cytokines was higher in CGRPÀ/À than wild type in the acute phase of ischemia. Pathological analysis during the chronic phase revealed more extensive neuronal cell loss and demyelination and higher levels of oxidative stress in CGRPÀ/À than wild-type. CGRPÀ/À also showed less compensatory capillary growth. In an eight-arm radial maze test, CGRPÀ/À exhibited poorer reference memory than wild-type. On the other hand, CGRP administration promoted cerebral blood flow recovery after cerebral ischemia. We also found that CGRP directly inhibited the cell death of primary cortical neurons.
INTRODUCTION
C erebrovascular diseases continue to be a major global health problem, especially in aging societies [1] , and novel primary prevention strategies and therapeutic approaches are much needed [2] . There are two major types of cerebrovascular diseases: cerebral ischemia and cerebral hemorrhage. Of those, cerebral ischemia accounts for the majority of cases. It is generally accepted that the main cause of cerebral ischemia is thrombosis in situ or embolic occlusion of a cerebral blood vessel, with the latter usually arising from the heart or atherosclerotic plaques in a carotid artery or aortic arch [3, 4] . The resultant loss of blood flow in the affected blood vessels leads to motor and sensory dysfunction. The mechanisms underlying hypoxic-ischemic brain damage include death of neuronal and glial cells and loss of integrity of the blood-brain barrier (BBB). Cerebral ischemia also increases the risk of developing dementia [5, 6] . The vascular dementia that often occurs after a stroke is an important aspect for stroke survivors and even minor strokes affect daily functioning [7, 8] . Prevention of vascular dementia can be achieved through the prevention and treatment of stroke. Therefore, the early recovery of cerebral blood flow (CBF) and therapy that includes inhibition of apoptosis and maintenance of the BBB may reverse the damage caused by cerebral ischemia and reduce the occurrence of vascular dementia.
Calcitonin gene-related peptide (CGRP) is a 37-amino acid peptide produced as a consequence of alternative RNA processing of the calcitonin gene. Originally identified as a strong vasodilatory neuropeptide, CGRP is primarily released from sensory nerves and is widely distributed in
MATERIALS AND METHODS

Experimental animals
CGRPÀ/À mice were generated by our group using a targeting DNA construct that replaced exon 5, encoding a CGRP-specific region [29] . Healthy male CGRPÀ/À and their wild-type littermates were selected for the acute and chronic cerebral ischemia models [10-12-week-old male mice for middle cerebral artery occlusion (MCAO), 9-weekold male mice for bilateral common carotid artery stenosis (BCAS)]. All animal manipulations were approved by the Ethics Committee of Shinshu University (Nagano, Japan).
Establishment of middle cerebral artery occlusion model
Acute cerebral ischemia-reperfusion injury was induced by unilateral MCAO, as described previously [30] . Male mice between 10 and 12 weeks of age were used. Before the start of the experiments, 1.5 cm of 6-0 nylon surgical suture was coated with silicone to prepare an embolic filament. Mice were anesthetized through continuous inhalation of isoflurane, and the common carotid, internal carotid and external carotid arteries of the right side were separated. Blood flow in the external carotid artery was permanently blocked using an electric knife. The common carotid was clipped, and then the embolic filament was inserted from the external carotid artery into the middle cerebral artery whenever faint resistance was felt. After 2 h of cerebral ischemia, the nylon line was removed and the incision was sutured. The vessels were reperfused for 22 h, after which the brain tissues were dissected for brain injury and gene expression analysis. CBF was recorded using an OMEGA-ZONEOZ-1 laser Doppler blood flow imaging system (Omegawave Inc., Tokyo, Japan). CBF was recorded just before and 2, 6, and 24 h after the surgery. The CBF values are expressed as percentages of the baseline value.
Establishment of bilateral common carotid artery stenosis model
Chronic cerebral ischemia was induced by BCAS, as described previously [31, 32] . Male, 9-week-old mice were anesthetized through continuous inhalation of isoflurane, and the common carotid artery was exposed. Two 4-0 silk sutures were then placed loosely around the distal and proximal parts of the right common carotid artery. Using the sutures, the artery was gently lifted, and an external microcoil (internal diameter: 0.18 mm) was attached just below the carotid bifurcation. In the same manner, a second microcoil of the same size was attached around the left common carotid artery. Mice in the sham group were subjected to the same surgery, but the microcoils were not attached. CBF was recorded using an OMEGAZO-NEOZ-1 laser Doppler blood flow imaging system prior to the operation, immediately after the operation, 2 h after the operation, and 1, 2, 7, 14, 21, and 28 days after the operation. The CBF values were expressed as percentages of the baseline value.
Behavioral analysis using an eight-arm radial maze test
To explore the behavioral changes caused by BCAS, behavioral analysis using an eight-arm radial maze (SMART v3.0.00; Panlab, Spain) was conducted as previously reported [28] . The maze consisted of a central platform (24 cm in diameter) with eight arms extending out radially. Before inducing BCAS, each mouse was trained twice per day for 8 days to memorize the apparatus. Food was then withheld for 15 h prior to the test, and the animals were allowed to visit the arms to eat pellets in food cups located near the end of each arm. The performance of the test animals in each trial was assessed using four parameters: working memory errors (numbers of revisits to the same arm over 5 min), reference memory errors (numbers of visits to the arm without a food pellet over 5 min), correct answers (numbers of visits to the arm with a food pellet among the initial four choices), and required time (the average time required to take all the food pellets). Beginning 28 days after induction of BCAS, we used the same test for 14 days to evaluate changes in behavior. After the behavioral tests, the brain tissues were dissected for pathology and gene expression analysis.
Histology
The brain tissue dissected from each mouse was fixed overnight in 4% paraformaldehyde, embedded in paraffin, and cut into 7-mm thick sections for histological analysis. The slices were deparaffinized for hematoxylin and eosin (H&E) staining, Kluver-Barrera staining, TUNEL (Terminal deoxynucleotidyl transferase dUTP Nick End Labeling) and immunohistochemical staining. For evaluation of nerve RNA extraction and quantitative real-time reverse transcription-PCR analysis Total RNA was extracted from tissues or cells using TRIzol Reagent (Thermo Fisher Scientific), after which the extracted RNA was treated with DNA-Free (Thermo Fisher Scientific) to remove contaminating DNA, and 2-mg samples were reverse transcribed using a High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). Quantitative real-time reverse transcription (RT)-PCR was carried out using an Applied Biosystems 7300 real time PCR System with SYBR green (Toyobo, Osaka, Japan) or Realtime PCR Master Mix (Toyobo) and TaqMan probe (MBL, Nagoya, Japan). The primers and probes used are listed in Table 1 . Values were normalized to mouse GAPDH (Pre-Developed TaqMan assay reagents; Thermo Fisher Scientific).
Administration of hydralazine to CGRPS/S and wild-type mice CGRPÀ/À and wild-type mice were orally administered hydralazine (Sigma-Aldrich, St. Louis, Missouri, USA; lot 055K1703) in their drinking water at a dose of 5 mg/kg per day. SBP was measured in conscious mice using a computerized tail-cuff method (BP-2000; Visitech Systems, Apex, North Carolina, USA). After 4 weeks of hydralazine administration, mice were subjected to BCAS, and CBF was monitored. After 42 days of BCAS, brain tissues were dissected for pathological analysis.
Continuous administration of calcitonin gene-related peptide to wild-type mice Eight-week-old male wild-type mice were subcutaneously administered human aCGRP (Peptide Institute, Inc., Osaka, Japan) at a concentration of 1 mmol/l in sterile physiological saline using osmotic pumps (Alzet; DORECT Co, Cupertino, California, USA). The delivery rate was 0.5 ml/h. SBP was monitored throughout the administration. Wild-type mice administered hydralazine in their drinking water at a dose of 5 mg/kg/day served as controls. After 2 weeks of CGRP or hydralazine administration, mice were subjected to BCAS, and CBF was monitored. After 28 days of BCAS, the brain tissues were dissected for pathological and gene expression analysis.
Primary cortical neuron culture
Cortical neurons were prepared from newborn C57BL/6 mice as described previously [33] . Briefly, the cerebral cortex was dissected and placed in ice-cold aseptic dissection solution [PBS(À)]. After mincing, the tissue was enzymatically digested with 0.1% DNase I (Sigma-Aldrich) and 1% trypsin for 5 min at room temperature and then mechanically dissociated. Neurons were seeded into poly-D-lysine-coated 24-multiwell plates at a density of 1 Â 10 5 viable cells/well. Cultures were maintained in Neurobasal A medium (Thermo Fisher Scientific) supplemented with 5% FBS, 2% B27 nutrient (Thermo Fisher Scientific), 0.5 mM L-glutamine, penicillin (100 U/ml) at 378C in 5% CO 2 . After 12 h of incubation, the medium was changed to serum-free Neurobasal A. We then used RT-PCR to examine expression of CGRP and adrenomedullin receptor components in primary cortical neurons. The primers used are listed in Table 2 . All experiments were carried out on mature neurons grown for 14 days in vitro.
Cell viability assay
Primary cortical neurons were stimulated with recombinant mouse TNF-a (200 ng/ml) (MerckMillipore, Billerica, Massachusetts, USA) for 72 h in the presence or absence of graded doses of CGRP. Human aCGRP was added to a concentration of 10 -9 -10 -7 mol/l 1 h before addition of TNF-a. After stimulation with TNF-a for 72 h, the viability of the cortical neurons was assessed using a WST-8 kit (Dojindo, Kumamoto, Japan) according to the manufacturer's instructions. 
Statistical analysis
Values are expressed as means AE SE. Student's t-test was used to determine significant differences between two groups. One-way ANOVA followed by Fisher's protected least significant difference was used to determine significant differences between three or more groups. All analyses were performed using SPSS software (v.19; SPSS Inc., Chicago, Illinois, USA). Values of P < 0.05 were considered significant.
RESULTS
CGRPS/S mice show delayed recovery of cerebral blood flow and more extensive neuronal cell damage after middle cerebral artery occlusion
We initially generated acute cerebral ischemia injury through MCAO. Laser Doppler images of CBF before and after the operation are shown in Fig. 1a . Immediately after the operation, both the infarcted and contralateral sides of the brain showed transiently diminished CBF. In both CGRPÀ/À and wild-type mice, CBF on the infarcted and contralateral sides were, respectively, reduced to about 80 and 60% of the preoperation level (Fig. 1b) . Although the CBF reduction on the infarcted side immediately after MCAO was nearly the same in wild-type and CGRPÀ/À mice, recovery of CBF at 6 and 24 h showed tendency of reduction in CGRPÀ/À (Fig. 1c) .
Pathological analysis 24 h after the final CBF measurements showed that CGRPÀ/À brains had more extensive neuronal cell damage in the cerebral cortex, corpus callosum and corpus striatum boundary region; cell density reduction, cellular vacuolation and nuclear alterations were all more apparent in the CGRPÀ/À than wild-type mice after MCAO (Fig. 2a-f ). In addition, TUNEL analysis showed a higher incidence of apoptosis on the operated side in CGRPÀ/À than wild-type mice ( Fig. 2g and h ), indicating more extensive irreversible cell damage.
Gene expression analysis of the cerebral cortex from wild-type mice revealed CGRP expression to be significantly higher in the MCAO group than the sham-operation group. In addition, CGRP's receptor, CLR, also tended to be upregulated in the MCAO groups of wild-type and CGRPÀ/ À mice (Fig. 3a) . This suggests CGRP-CLR signaling is involved in the pathogenesis of acute cerebral infarction induced by MCAO. On the other hand, the CGRP receptor's modifying protein, RAMP1, was unchanged or somewhat decreased in the MCAO group. Interestingly, expression of adrenomedullin, a related peptide, was elevated by MCAO. Expression of adrenomedullin receptor's modifying protein, RAMP2 and 3, was also elevated by MCAO, which may reflect compensatory upregulation of adrenomedullin signaling in brain ischemia. CGRPÀ/À brains showed significantly increased expression of adrenomedullin in the cerebral cortex. As adrenomedullin is a vasodilating peptide, like CGRP, this may reflect compensation for the CGRP deficiency in CGRPÀ/À brains. Similarly, in the hippocampus, CGRP expression tended to be higher on the operated side in the MCAO group of wild-type mice (Fig. 3b) . Adrenomedullin expression also tended to be upregulated in the MCAO groups and was more apparent in CGRPÀ/À brains. In addition, in both the cerebral cortex and hippocampus on the operated side in the MACO group, levels of IL1b, IL-6 and TNF-a, three inflammatory cytokines, were significantly higher in CGRPÀ/À than wild-type brains. Taken together, these results indicate that after MCAO, CGRPÀ/À mice showed extensive neuronal cell damage with greater upregulation of inflammatory cytokines than was seen in wild-type mice ( Fig. 3a and b) .
CGRPS/S mice show delayed recovery of cerebral blood flow and decreased body weight after bilateral common carotid artery stenosis
We next examined the effects of chronic cerebral ischemia in CGRPÀ/À and wild-type mice caused by BCAS produced by attaching a coil to bilateral common carotid arteries. Figure 4a shows the time course of the BCAS analysis. Wildtype and CGRPÀ/À mice underwent pretraining in an eight-arm radial maze for 8 days before the BCAS operation was performed. After recording the changes in CBF and body weight for 28 days after placement of the coils, we examined mice's behavior for 14 days using the eight-arm radial maze.
Laser Doppler images of CBF before and after the operation are shown in Fig. 4b . Immediately after the operation, CBF in wild-type and CGRPÀ/À mice was, respectively, reduced to about 70 and 55% of the pre-BCAS level (Fig. 4c) . Two hours after the operation, CBF had recovered to about 80% in both wild-type and CGRPÀ/À mice. In the chronic phase of BCAS, however, CGRPÀ/À mice showed slower recovery of CBF. Fourteen and 28 days post-BCAS, CBF was significantly lower in CGRPÀ/À than wild-type mice (Fig. 4c) .
After the BCAS operation, transient body weight reduction was observed in both wild-type and CGRPÀ/À mice; however, the effect was more pronounced in CGRPÀ/À mice. The body weights 2 and 7 days post-BCAS were significantly lower in CGRPÀ/À than wild-type mice (Fig. 4d) .
CGRPS/S mice show more extensive neuronal cell loss, glial cell activation and less compensatory capillary growth after bilateral common carotid artery stenosis
To analyze the changes early during BCAS, we performed a pathological analysis after 1 or 3 days of BCAS. On day 1 of BCAS, CGRPÀ/À mice exhibited a greater reduction in neuronal cells in the cerebral cortex ( Fig. 5a and b) and corpus callosum ( Fig. 5c and d ) than wild-type mice. In addition, numbers of GFAP-positive astrocytes in the corpus striatum boundary region ( Fig. 5e and f) , cerebral cortex ( Fig. 5g and h ), and hippocampus ( Fig. 5i and j) were higher on day 1 after BCAS in CGRPÀ/À mice, indicating there was greater activation of glial cells in CGRPÀ/À than wild-type mice. On day 3 of BCAS, CGRPÀ/À mice showed less CD31-positive capillary growth in the cerebral cortex ( Fig. 5k and l) and corpus callosum ( Fig. 5m and n) than wild-type mice.
CGRPS/S mice show extensive neuronal cell loss, demyelination, astrocyte activation, oxidative stress and less compensatory capillary formation in the chronic stage of bilateral common carotid artery stenosis
To analyze the changes in the chronic stage of BCAS, we performed a pathological analysis after 42 days of BCAS. H&E staining showed greater neuronal cell loss in the cerebral cortex of CGRPÀ/À than wild-type mice (Fig. 6a and b) . Kluver-Barrera staining of brain sections revealed that the number of cresyl violet-stained neurons in the cerebral cortex and the amount of luxol fast blue-stained myelin in the corpus striatum boundary region was lower in CGRPÀ/À than wild-type brains (Fig. 6c-h ), which indicates more extensive neuronal cell loss and demyelination in CGRPÀ/À brains. CGRPÀ/À brains also had greater numbers of GFAP-positive astrocytes (Fig. 6i-n stress were assessed based on the extent of oxidative DNA damage indicated by 8-OHdG immunostaining. We found that 8-OHdG levels were higher in CGRPÀ/À than wild-type brains ( Fig. 6o and p) . In addition, CGRPÀ/À brains showed less CD31-positive capillary formation in the cerebral cortex and hippocampus dentate gyrus than wild-type brains ( Fig. 6q-t) .
CGRPS/S mice show upregulation of inflammatory cytokines and downregulation of angiogenic factors after bilateral common carotid artery stenosis
Using real-time RT-PCR, we analyzed gene expression after 1, 3, and 42 days of BCAS. The results showed that on day 3 of BCAS in wild-type mice, CGRP expression was significantly higher in the BCAS group than the sham-operated group. In addition, CGRPÀ/À mice showed significantly higher CLR expression than wild-type mice on day 42 of BCAS ( Fig. 7a) . At days 3 and 42 of BCAS, the expression of adrenomedullin showed tendency of elevation by BCAS in both wild-type and CGRPÀ/À mice. At day 3 of BCAS, the expressions of RAMP1, RAMP3, and CLR also showed tendency of elevation in both wild-type and CGRPÀ/À mice. Elevation of RAMP1 and CLR may indicate that CGRP-CLR-RAMP1 signaling is involved in the pathogenesis of chronic cerebral infarction induced by BCAS. Elevation of adrenomedullin, RAMP3 and CLR may represent the compensatory upregulation of adrenomedullin-CLR-RAMP3 signaling in the subacute phase of BCAS. Interestingly, cerebrocortical expression of two inflammatory cytokines, IL-6 and TNF-a, was significantly higher in CGRPÀ/À than wild-type brains on day 1 of BCAS ( Fig. 7b) . This result is consistent with the observation after MCAO, and indicates that CGRPÀ/À mice had greater inflammation during the early stage of ischemia after both In wildtype mice subjected to BCAS, about 80% recovery of CBF was maintained on day 28 after BCAS. CGRPÀ/À showed a slower recovery, and CBF on days 14 and 28 after BCAS was significantly lower than in wild-type mice. MCAO and BCAS. In addition, cerebrocortical expression of the angiogenic factors VEGF-A and IGF-1 was lower in CGRPÀ/À than wild-type brains on day 3 of BCAS ( Fig. 7c) . This result is consistent with the observed decrease in capillary formation seen in CGRPÀ/À brains in the pathological analysis, and indicates that CGRP deficiency may decrease compensative capillary formation after cerebral ischemia.
CGRPS/S mice exhibit increased blood-brain barrier damage-related factors after bilateral common carotid artery stenosis
We also assessed expression of BBB damage-related factors on day 42 of BCAS. The levels of AQP4 and MMP9 in the cerebral cortex (Fig. 8a) and the level of AQP4 in the hippocampus (Fig. 8b) were significantly higher in CGRPÀ/À than wild-type brains. This suggests CGRP deficiency leads to greater BBB damage during chronic cerebral ischemia.
CGRPS/S mice exhibit greater cognitive disorder after bilateral common carotid artery stenosis
We used an eight-arm radial maze for behavioral analysis. During 8 days of training before the BCAS operation (training period), there was no difference in the performances of wild-type and CGRPÀ/À mice (Fig. 9a) . On day 8 of postoperative behavior analysis (day 36 of BCAS), the reference memory error (numbers of visits to the arm without a food pellet over 5 min) was significantly higher in CGRPÀ/À mice, whereas the correct answers (numbers of visits to the arm with a food pellet during the initial four choices) were significantly lower in CGRPÀ/À than wildtype mice (Fig. 9b) . These results indicate that CGRPÀ/À mice had more severe disturbance of memory after BCAS than wild-type mice.
The difference in blood pressure in CGRPS/S mice does not affect cerebral blood flow or brain injury
As CGRP exerts vasodilatory effects, directly measured mean arterial pressure using a catheter inserted into the femoral arteries of mice was reported to be slightly elevated in CGRPÀ/À [29] . To rule out an effect of the blood pressure difference between wild-type and CGRPÀ/À mice, we administered hydralazine (an antihypertensive drug) to both groups and evaluated the CBF and brain injury induced by BCAS in each mouse. Oral administration of hydralazine for 4 weeks in the drinking water (5 mg/kg per day) lowered blood pressures and effectively eliminated the difference in blood pressure between the CGRPÀ/À and wild-type mice (Fig. 10a) . Nevertheless, CBF recovery tended to be slower in CGRPÀ/À than wild-type mice (Fig. 10b) , and the brain injury was still more severe with greater neuronal cell loss in CGRPÀ/À mice ( Fig. 10c  and d ). When we used Bodian's staining to evaluate injury to neurofibrils, we detected greater reductions of neurofibrils in CGRPÀ/À than wild-type mice (Fig. 10e and f) . These observations indicate that the difference in baseline blood pressures did not account for the delayed CBF recovery and more severe brain injury in CGRPÀ/À mice.
Calcitonin gene-related peptide administration promotes cerebral blood flow recovery, suppresses astrocyte activation and increases angiogenesis after cerebral ischemia
To further rule out the effect of blood pressure and to verify the protective effects of endogenous CGRP, we administered CGRP or hydralazine to wild-type mice for 2 weeks prior to BCAS. During the experiment, we monitored the changes in both blood pressure and CBF. SBP was reduced to about 80 mmHg after administration of either hydralazine or CGRP. Before and after the BCAS operation, blood pressures did not differ between the two groups (Fig. 11a) . On the other hand, CBF was significantly higher after 7, 14, and 28 days of BCAS in the CGRP group than the hydralazine group (Fig. 11b) . These results suggest CGRP administration enhances the recovery of CBF after cerebral ischemia. After monitoring blood pressure and CBF for 28 days, we analyzed the pathological changes and gene expression. The pathological results showed that the neuronal cell loss in the cerebral cortex ( Fig. 11c and d) and numbers of GFAP-positive astrocytes in the cerebral cortex and corpus callosum were lower in the CGRP group than the hydralazine group (Fig. 11e-h) . Moreover, the CGRP group showed greater CD31-positive capillary formation than the hydralazine group (Fig. 11i-l) . Thus, CGRP administration appears to promote CBF recovery and capillary formation whereas suppressing astrocyte activation and inflammatory cytokine expression to reduce neuronal cell injury after cerebral ischemia and these effects are independent of any change in blood pressure.
Calcitonin gene-related peptide inhibits TNF-ainduced apoptosis in primary cortical neuron culture
Finally, we directly investigated the protective effect of CGRP against neuron death using cultures of primary cortical neurons stimulated for 72 h with 200 ng/ml TNF-a in the presence or absence of graded doses of CGRP. CGRP was added 1 h prior to addition of TNF-a. RT-PCR was used to identify CGRP receptor components expressed by the cortical neurons. We found that the neurons expressed mRNAs for CLR and its three accessory protein proteins, RAMP1, RAMP2 and RAMP3 (Fig. 12a) . Survival of the primary cortical neurons was reduced to about 70% by TNF-a stimulation, but CGRP (10 À7 mol/l) treatment suppressed that effect (Fig. 12b) .
DISCUSSION
Despite recent advances in neuroimaging technologies, which enable us to diagnose stroke quickly, brain injury Data from the sham-operated wild-type mice on each day was assigned a value of 1, and values were expressed as the mean AE SEM. CGRPÀ/À mice showed increased expression of IL-6 and TNF-a and decreased expression of VEGF-A and IGF-1 early after BCAS. and cognitive impairment induced by stroke continue to be a leading cause of morbidity and mortality. The most common cause of stroke is cerebral ischemia [34] , which is characterized by a reduction in CBF resulting from thromboembolic occlusion of a major cerebral artery or its branches. The reduction of CBF leads to loss of oxygen and nutrient supply to nerve cells, causing metabolic and functional deficits. In addition, hypertension is the most common risk factor for cerebral ischemia. Consequently, effective control of blood pressure and timely recovery of CBF to the ischemic regions are very critical for improving stroke prognosis and promoting functional recovery. For that reason, endogenous vasoactive molecules that improve CBF have attracted our attention. Initially, adrenomedullin, a pleiotropic vasoactive molecule, appeared to be a promising research target. In past studies, we showed that homozygous knockout mice of either adrenomedullin or RAMP2 is embryonically lethal because of abnormal vascular development [35, 36] . In addition, we reported the neuroprotective effect of endogenous adrenomedullin in acute and chronic cerebral ischemia models [28] . However, the significance of CGRP, an adrenomedullin family peptide, in cerebral ischemia, remains unknown. In the present study, therefore, we investigated the pathophysiological significance of CGRP in cerebral ischemia.
In the heart, CGRP exerts a protective effect against cardiac ischemia-reperfusion injury and pressure overload-induced heart failure [19, 37] . CGRP is also protective at the onset of vessel injury and remodeling [38] , and it plays a protective role against neointimal hyperplasia following wire-induced vascular injury [39] . Collectively, these results are indicative of the vasoprotective actions for CGRP, which contribute to the maintenance of cardiac and vascular homeostasis.
In the present study, we demonstrated that CGRP deficiency leads to delayed CBF recovery in acute and chronic cerebral ischemia models, which suggests CGRP plays a key role in maintaining CBF. We also found that CGRP gene expression is upregulated on the infarcted side after MCAO and BCAS in wild-type mice, which suggests this upregulation is a compensatory response to cerebral ischemia. Interestingly, adrenomedullin gene expression was also upregulated after cerebral ischemia in both wild-type and CGRPÀ/À mice, and the elevation was greater in CGRPÀ/À than wild-type mice. This suggests the increase in adrenomedullin is a compensatory response to the CGRP deficiency in CGRPÀ/À mice. Endogenous CGRP, thus, appears to exert protective effects in an effort to maintain CBF during cerebral ischemia.
CGRP exerts vasodilatory effects, however, in the present study, we demonstrated that the difference in blood pressure in CGRPÀ/À mice does not affect CBF or brain injury. In addition, from the results of CGRP or hydralazine administration to wild-type mice, we found that CGRP administration promoted the recovery of CBF and reduced neuronal cell injury, which is independent of any change in blood pressure. Taken together, endogenous CGRP plays a protective role in maintaining CBF and reducing nerve injury independent of blood pressure.
The inflammatory response and oxidative stress that follow cerebral ischemia exacerbates the brain damage and neurological deficits, and they play a central role in the pathogenesis and progression of stroke. It has been reported that CGRP plays a key role in inflammation [24, 25] , though whether the actions of CGRP are proinflammatory or anti-inflammatory remain controversial. In the present study, we found that expression of inflammatory cytokines was higher in CGRPÀ/À than wild-type mice early after induction of ischemia in both the MCAO and BCAS models. This result is consistent with the increased activation of astrocytes in CGRPÀ/À seen after MCAO and BCAS and suggests CGRP has an anti-inflammatory function after cerebral ischemia, which may be one aspect of its protective effect during cerebral ischemia. In addition, we found higher levels of oxidative stress in CGRPÀ/À than wildtype mice after BCAS, suggesting antioxidative effects of CGRP are also involved in the protection against cerebral ischemia. Thus, CGRP may protect against cerebral ischemia by suppressing both inflammation and oxidative stress to some extent.
Preventing the occurrence of neuronal cell loss is the ultimate goal of treatment for cerebral ischemia. CGRP reportedly protects cultured smooth muscle cells from apoptosis induced by oxidative stress via activation of ERK1/2 MAPK [40] , and CGRP protects cardiomyocytes from hypoxia-induced inflammation and apoptosis by modulating NO production [41] . In addition, we have reported that CGRP exerts a hepatoprotective effect by modulating cytokine expression and preventing apoptosis [42] . In the present study, the incidence of apoptosis and neuronal cell loss after cerebral ischemia was higher in CGRPÀ/À than wild-type mice, suggesting CGRP exerts an antiapoptotic effect. To verify the direct beneficial effects of CGRP on neurons cells, we induced apoptosis in primary cortical neurons by exposing them to TNF-a in their culture medium with and without CGRP. The result showed that CGRP inhibits TNF-a-induced apoptosis in primary cortical neurons, suggesting CGRP directly protects neurons by preventing apoptosis, and this effect would be independent of its beneficial effect on CBF. Recent studies have shown that new vessel formation after stroke not only replenishes the blood flow to ischemic regions of the brain, but also promotes neurogenesis and improves neurological function. Therefore, drugs that can promote angiogenesis after cerebral ischemia can provide therapeutic benefits during stroke treatment. CGRP reportedly exhibits angiogenic activity in various ischemic disease models [20, 21] . In the present study, we found that CGRPÀ/ À mice showed less compensatory capillary growth during chronic cerebral ischemia, suggesting CGRP promotes angiogenesis after cerebral ischemia. However, the specific mechanism remains to be determined.
Vascular dementia is the second most common type of dementia after Alzheimer disease, and stroke increases the risk of this type of dementia. In stroke survivors, the prevalence of vascular dementia is about 30%, and dementia is one of the major cause of dependency after stroke [5] . In contrast to Alzheimer disease, there is great hope that vascular contributions to cognitive impairment can be prevented and treated; that is, effective prevention and treatment of cerebral ischemia is expected to reduce the incidence of dementia. Singh et al. [43] recently reported that CGRP is protective against Alzheimer disease. However, the role of CGRP in vascular dementia induced by cerebral ischemia remains unknown. In the present study, we used an eight-arm radial maze to evaluate the behavioral changes during BCAS in wild-type and CGRPÀ/À mice. The result showed that CGRPÀ/À mice experienced more severe cognitive disorder during BCAS, which suggests CGRP may improve cognitive ability after cerebral ischemia. In addition, we found that factors related to BBB damage were upregulated during BCAS in CGRPÀ/À mice, indicating disruption of the BBB. Studies have shown there is a significant association between BBB dysfunction and vascular cognitive impairment [44] . Thus, cognitive disorder caused by BCAS in CGRPÀ/À mice may be in part attributable to damage to the BBB.
Directly measured mean arterial pressure using a catheter inserted into the mice femoral arteries was found to be slightly higher in CGRPÀ/À than wild-type mice at baseline [29] . To rule out an effect of the blood pressure difference between wild-type and CGRPÀ/À mice, in this study, we administered hydralazine to both groups and evaluated the CBF and brain injury induced by BCAS in each mouse. We observed that CBF recovery was slower in CGRPÀ/À than wild-type mice, and the brain injury was still more severe with greater neuronal cell loss in CGRPÀ/À mice. These observations indicate that the difference in baseline blood pressures did not contribute much to the poorer cerebral outcomes in CGRPÀ/À mice.
In conclusion, we have demonstrated that CGRP contributes to improving CBF recovery after cerebral ischemia. CGRP may also suppress inflammation and oxidative stress, promote angiogenesis and exert a direct antiapoptotic effect. In addition, CGRP can mitigate the cognitive disorder induced by cerebral ischemia, which is partly attributed to an effect that decreases BBB damage. These results indicate that endogenous CGRP exerts significant neuroprotective effects during cerebral ischemia, and targeting CGRP may be a promising approach to treating cerebral ischemia and cognitive decline. Research and Development (AMED), National Cardiovascular Center research grant for cardiovascular diseases, FIGURE 12 Protective effect of calcitonin gene-related peptide against TNF-ainduced death in primary cortical neurons. (a) Total RNA was extracted from primary cortical neurons and subjected to RT-PCR with primers specific for CLR, RAMP1, RAMP2, RAMP3, and Hprt. The expected sizes for the amplified fragments were 788 bp for CLR, 704 bp for RAMP1, 313 bp for RAMP2, 100 bp for RAMP3, and 352 bp for Hprt. (b) Protective effect of CGRP against TNF-a-induced death in primary cortical neurons from newborn C57BL/6 mice. Cell viability of cortical neurons was assessed using a WST-8 kit. Data from the control group was assigned a value of 100, and values were expressed as the mean AE SEM. After 72 h of stimulation in the presence of 200 ng/ml TNF-a, the cell viability of primary cortical neurons reduced to about 70%. CGRP (10 À7 mol/l) significantly reduced the incidence of cell death induced by TNF-a treatment.
